Cargando…

Influence of equipment changes on MRI measures of brain atrophy and brain microstructure in a placebo-controlled trial of ibudilast in progressive multiple sclerosis

BACKGROUND: Hardware changes can be an unavoidable confound in imaging trials. Understanding the impact of such changes may play an important role in the analysis of imaging data. OBJECTIVE: To characterize the effect of equipment changes in a longitudinal, multi-site multiple sclerosis trial. METHO...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sakaie, Ken, Fedler, Janel K, Yankey, Jon W, Nakamura, Kunio, Debbins, Josef, Lowe, Mark J, Raska, Paola, Fox, Robert J
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2021
Materias:	Original Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8138298/ https://www.ncbi.nlm.nih.gov/pubmed/34046185 http://dx.doi.org/10.1177/20552173211010843

Ejemplares similares

Response to ibudilast treatment according to progressive multiple sclerosis disease phenotype
por: Goodman, Andrew D., et al.
Publicado: (2021)

Ibudilast (MN-166) in amyotrophic lateral sclerosis- an open label, safety and pharmacodynamic trial
por: Babu, Suma, et al.
Publicado: (2021)

Role of phosphodiesterase inhibitor Ibudilast in morphine-induced hippocampal injury
por: Zhaleh, Mohsen, et al.
Publicado: (2014)

The phosphodiesterase inhibitor, ibudilast, attenuates neuroinflammation in the MPTP model of Parkinson’s disease
por: Schwenkgrub, Joanna, et al.
Publicado: (2017)

Signal Transduction of Improving Effects of Ibudilast on Methamphetamine Induced Cell Death
por: Tahvilian, Reza, et al.
Publicado: (2019)

Ibudilast sensitizes glioblastoma to temozolomide by targeting Macrophage Migration Inhibitory Factor (MIF)
por: Ha, Wendy, et al.
Publicado: (2019)

Sex differences in brain atrophy in multiple sclerosis
por: Voskuhl, Rhonda R., et al.
Publicado: (2020)

A double-blind, randomized, placebo-controlled pilot trial to determine the efficacy and safety of ibudilast, a potential glial attenuator, in chronic migraine
por: Kwok, Yuen H, et al.
Publicado: (2016)

Ibudilast Mitigates Delayed Bone Healing Caused by Lipopolysaccharide by Altering Osteoblast and Osteoclast Activity
por: Chang, Yuhan, et al.
Publicado: (2021)

Ibudilast for alcohol use disorder: study protocol for a phase II randomized clinical trial
por: Burnette, Elizabeth M., et al.
Publicado: (2020)

Emerging Potential of the Phosphodiesterase (PDE) Inhibitor Ibudilast for Neurodegenerative Diseases: An Update on Preclinical and Clinical Evidence
por: Angelopoulou, Efthalia, et al.
Publicado: (2022)

Revisiting Brain Atrophy and Its Relationship to Disability in Multiple Sclerosis
por: Shiee, Navid, et al.
Publicado: (2012)

Association of Retinal and Macular Damage with Brain Atrophy in Multiple Sclerosis
por: Dörr, Jan, et al.
Publicado: (2011)

Reliable measurements of brain atrophy in individual patients with multiple sclerosis
por: Smeets, Dirk, et al.
Publicado: (2016)

Anti-inflammatory therapy by ibudilast, a phosphodiesterase inhibitor, in demyelination of twitcher, a genetic demyelination model
por: Kagitani-Shimono, Kuriko, et al.
Publicado: (2005)

Altered Brain Volume, Microstructure Metrics and Functional Connectivity Features in Multiple System Atrophy
por: Ge, Yunxiang, et al.
Publicado: (2022)

Exploratory MRI measures after intravenous autologous culture-expanded mesenchymal stem cell transplantation in multiple sclerosis
por: Feng, Jenny, et al.
Publicado: (2019)

Establishing pathological cut-offs of brain atrophy rates in multiple sclerosis
por: De Stefano, Nicola, et al.
Publicado: (2016)

Brain atrophy in multiple sclerosis: mechanisms, clinical relevance and treatment options
por: Andravizou, Athina, et al.
Publicado: (2019)

Patterns of brain atrophy in recently-diagnosed relapsing-remitting multiple sclerosis
por: Meijboom, Rozanna, et al.
Publicado: (2023)

Thalamic Atrophy Without Whole Brain Atrophy Is Associated With Absence of 2-Year NEDA in Multiple Sclerosis
por: Hänninen, Katariina, et al.
Publicado: (2019)

Evaluation of a connectivity-based imaging metric that reflects functional decline in Multiple Sclerosis
por: Koenig, Katherine A., et al.
Publicado: (2021)

Effects of Dimethyl Fumarate on Brain Atrophy in Relapsing-Remitting Multiple Sclerosis: Pooled Analysis Phase 3 DEFINE and CONFIRM Studies
por: Nakamura, Kunio, et al.
Publicado: (2022)

Ibudilast, a Pharmacologic Phosphodiesterase Inhibitor, Prevents Human Immunodeficiency Virus-1 Tat-Mediated Activation of Microglial Cells
por: Kiebala, Michelle, et al.
Publicado: (2011)

Ibudilast, a Phosphodiesterase-4 Inhibitor, Ameliorates Acute Respiratory Distress Syndrome in Neonatal Mice by Alleviating Inflammation and Apoptosis
por: Yang, Dongjie, et al.
Publicado: (2020)

Ibudilast, a neuroimmune modulator, reduces heavy drinking and alcohol cue-elicited neural activation: a randomized trial
por: Grodin, Erica N., et al.
Publicado: (2021)

Brain MRI lesions and atrophy are associated with employment status in patients with multiple sclerosis
por: Tauhid, Shahamat, et al.
Publicado: (2015)

A regional consensus recommendation on brain atrophy as an outcome measure in multiple sclerosis
por: Alroughani, Raed, et al.
Publicado: (2016)

Regional Brain Atrophy and Functional Connectivity Changes Related to Fatigue in Multiple Sclerosis
por: Cruz Gómez, Álvaro Javier, et al.
Publicado: (2013)

Free serum haemoglobin is associated with brain atrophy in secondary progressive multiple sclerosis
por: Lewin, Alex, et al.
Publicado: (2016)

Brain atrophy measurement over a MRI scanner change in multiple sclerosis
por: Sinnecker, Tim, et al.
Publicado: (2022)

Brain Atrophy as an Outcome of Disease-Modifying Therapy for Remitting-Relapsing Multiple Sclerosis
por: Chylińska, Magdalena, et al.
Publicado: (2023)

Brain Atrophy as a Measure of Neuroprotective Drug Effects in Multiple Sclerosis: Influence of Inflammation
por: Koudriavtseva, Tatiana, et al.
Publicado: (2016)

Brain atrophy patterns in multiple sclerosis patients treated with natalizumab and its clinical correlates
por: Rekik, Arwa, et al.
Publicado: (2022)

Choroid plexus volume in multiple sclerosis predicts expansion of chronic lesions and brain atrophy
por: Klistorner, Samuel, et al.
Publicado: (2022)

Sex differences in brain atrophy in dementia with Lewy bodies
por: Oltra, Javier, et al.
Publicado: (2023)

Recommendations to improve imaging and analysis of brain lesion load and atrophy in longitudinal studies of multiple sclerosis
por: Vrenken, H., et al.
Publicado: (2012)

Brain atrophy and disability worsening in primary progressive multiple sclerosis: insights from the INFORMS study
por: Miller, David H., et al.
Publicado: (2018)

Brain atrophy and employment in multiple sclerosis patients: a 10-year follow-up study
por: Jacobsen, Cecilie, et al.
Publicado: (2020)

A matter of atrophy: differential impact of brain and spine damage on disability worsening in multiple sclerosis
por: Ruggieri, Serena, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_dolce1rn53pgskv35d341g804k